ScripRoivant Sciences Ltd. and Pfizer Inc. officially launched Priovant Therapeutics on 28 June to develop Pfizer’s TYK2/JAK1 inhibitor brepocitinib, but the companies had been working together since
Pink SheetThe number of investigational drugs that the European Medicines Agency accepted onto PRIME, its scheme for medicines that have the potential to address unmet medical needs, dropped sharply in 2021. Ju